Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Experimental Therapeutics for the Treatment of Osteoarthritis

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Schulze-Tanzil,Gundula
  • نوع التسجيلة:
    Electronic Resource
  • الدخول الالكتروني :
    https://www.dovepress.com/experimental-therapeutics-for-the-treatment-of-osteoarthritis-peer-reviewed-fulltext-article-JEP
    info:eu-repo/semantics/altIdentifier/doi/10.2147/JEP.S237479
  • معلومة اضافية
    • Publisher Information:
      Dove Press 2021-02-11
    • نبذة مختصرة :
      Gundula Schulze-Tanzil Department of Anatomy and Cell Biology, Paracelsus Medical University, Nuremberg, Bavaria, GermanyCorrespondence: Gundula Schulze-Tanzil Email gundula.schulze@pmu.ac.atAbstract: Osteoarthritis (OA) therapy remains a large challenge since no causative treatment options are so far available. Despite some main pathways contributing to OA are identified its pathogenesis is still rudimentary understood. A plethora of therapeutically promising agents are currently tested in experimental OA research to find an opportunity to reverse OA-associated joint damage and prevent its progression. Hence, this review aims to summarize novelly emerging experimental approaches for OA. Due to the diversity of strategies shown only main aspects could be summarized here including herbal medicines, nanoparticular compounds, growth factors, hormones, antibody-, cell- and extracellular vesicle (EV)-based approaches, optimized tools for joint viscosupplementation, genetic regulators such as si- or miRNAs and promising combinations. An abundant multitude of compounds obtained from plants, environmental, autologous or synthetic sources have been identified with anabolic, anti-inflammatory, -catabolic and anti-apoptotic properties. Some ubiquitous signaling pathways such as wingless and Integration site-1 (Wnt), Sirtuin, Toll-like receptor (TLR), mammalian target of rapamycin (mTOR), Nuclear Factor (NF)-κB and complement are involved in OA and addressed by them. Hyaluronan (HA) provided benefit in OA since many decades, and novel HA formulations have been developed now with higher HA content and long-term stability achieved by cross-linking suitable to be combined with other agents such as components from herbals or chemokines to attract regenerative cells. pH- or inflammation-sensitive nanoparticular compounds could serve as versatile slow-release systems of active compounds, for example, miRNAs. Some light has been brought into the intimate regulatory network o
    • الموضوع:
      Journal of Experimental Pharmacology; Review; info:eu-repo/semantics/article
    • Availability:
      Open access content. Open access content
      info:eu-repo/semantics/openAccess
    • Note:
      text/html
      English
    • Other Numbers:
      NZDMP oai:dovepress.com/61976
      1239727166
    • Contributing Source:
      DOVE MEDL PRESS LTD
      From OAIster®, provided by the OCLC Cooperative.
    • الرقم المعرف:
      edsoai.on1239727166
HoldingsOnline